Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 2/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871312 | 0.92 | KIF11 (0.46) | KIF11GNRHRSLC26A6BRD4SMN1; SMN2 | |
| SCHEMBL4059943 | 0.91 | TSHR (0.39) | KIF11POLBGNRHRSLC26A6BRD4 | |
| SCHEMBL4044893 | 0.85 | KIF11 (0.42) | KIF11POLBGAAGNRHRBRD4 | |
| SCHEMBL4044332 | 0.82 | KIF11 (0.52) | KIF11 | |
| SCHEMBL3901568 | 0.81 | KIF11 (0.49) | KIF11GNRHRSLC26A6BRD4SMN1; SMN2 | |
| SCHEMBL4218137 | 0.81 | KIF11 (0.49) | KIF11POLBGAAGNRHR | |
| SCHEMBL4065655 | 0.81 | KIF11 (0.43) | KIF11POLBSLC26A6BRD4SMN1; SMN2 | |
| SCHEMBL13956802 | 0.78 | KIF11 (0.46) | KIF11GNRHRBRD4DYRK1A | |
| SCHEMBL3863849 | 0.77 | KIF11 (0.49) | KIF11GAAGNRHRBRD4DYRK1A | |
| SCHEMBL4061532 | 0.77 | KIF11 (0.41) | KIF11GNRHRBRD4PLK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | KIF11 1978/4885POLB 2413/4885GAA 4453/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | KIF11 1978/4885POLB 2413/4885GAA 4453/4885 |
| US-20060270689-A1 | Novel Fused Heterocycles and Uses Thereof | BRCA1, CYP1B1, CCNI | KIF11 3559/4885POLB 1916/4885GAA 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.